OSE IMMUNOTHERAPEUTICS |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.14 EUR | +3.72% |
|
+0.16% | +43.69% |
| 24/06 | OSE: market welcomes CAR-T agreement | CF |
| 24/06 | OSE Immunotherapeutics SA Enters into a Commercial and Revenue Sharing Agreement with Memorial Sloan Kettering Cancer Center | CI |
Presenter SpeechUnknown Executive (Executives)Hello. Welcome to OSE Immunotherapeutics Key Opi...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
OSE Immunotherapeutics develops first-in-class assets in immuno-oncology (IO) & immuno-inflammation (I&I). The Company's current well-balanced first-in-class clinical pipeline includes:
- Tedopi® (lung cancer vaccine): positive Phase 3 results in NSCLC. Other Phase 2 trials of Tedopi® in combination are ongoing in solid tumors;
- OSE-279 (anti-PD1): Phase 1/2 positive results in solid tumors;
- OSE-127/Lusvertikimab (humanized monoclonal antibody antagonist of IL-7 receptor): Phase 2 in Ulcerative Colitis. Preclinical research in leukemia;
- FR-104/VEL-101 (anti-CD28 mAb): partnership with Veloxis in transplantation; Phase 1/2 in renal transplant (CHU Nantes);
- BI 765063/BI 770371 (anti-SIRP? mAb): partnership with Boehringer Ingelheim in advanced solid tumors;
- OSE-230 (ChemR23 agonist mAb): partnership with AbbVie in chronic inflammation.
OSE Immunotherapeutics expects to generate further significant value from its three proprietary drug discovery platforms:
- Pro-resolutive mAb platform focused on targeting and advancing inflammation resolution in I&I;
- Myeloid Checkpoint platform focused on optimizing the therapeutic potential of myeloid cells in IO;
- Cytokine platform focused on leveraging the Cis-Delivery of cytokine in IO and I&I.
Calendar
26/09/2024
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.92
EUR
Average target price
7.15
EUR
Spread / Average Target
+20.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +43.69% | 14Cr | |
| +38.36% | 5.27TCr | |
| +38.68% | 3.9TCr | |
| -8.63% | 3.85TCr | |
| +25.46% | 3.04TCr | |
| -11.17% | 2.64TCr | |
| +11.44% | 2.61TCr | |
| +45.09% | 1.42TCr | |
| +32.93% | 1.26TCr | |
| -5.30% | 1.15TCr |
- Stock Market
- Equities
- OSE Stock
- News OSE Immunotherapeutics
- Transcript : OSE Immunotherapeutics SA - Special Call
